Technical Analysis for ZIOP - ZIOPHARM Oncology Inc

Grade Last Price % Change Price Change
grade F 2.27 -8.47% -0.21
ZIOP closed down 8.47 percent on Friday, January 18, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ZIOP trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup -8.47%
Jan 17 Wide Bands Range Expansion -8.47%
Jan 16 Pocket Pivot Bullish Swing Setup -2.16%
Jan 16 Wide Bands Range Expansion -2.16%
Jan 15 NR7 Range Contraction 4.13%
Jan 15 Wide Bands Range Expansion 4.13%
Jan 14 Weak + Overbought Other 0.89%
Jan 14 Wide Bands Range Expansion 0.89%
Jan 14 Overbought Stochastic Strength 0.89%

Older signals for ZIOP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer. The company's portfolio of clinical-stage product candidates also includes ZIN-CTI-001, which is in Phase Ib clinical trial in patients with metastatic melanoma; ZIN-ATI-001, which is in Phase 1b clinical trial in patients with late-stage melanoma; Indibulin (ZIO-301), a novel, tubulin binding agent in Phase I/II clinical trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial-and hedgehog-targeted agent. In addition, it is developing oral capsule form of palifosfamide. The company has an exclusive channel partner agreement with Intrexon Corporation in which the company uses Intrexon Corporation technology directed towards in vivo expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York.
Is ZIOP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.21
52 Week Low 1.56
Average Volume 2,230,900
200-Day Moving Average 3.1694
50-Day Moving Average 2.6338
20-Day Moving Average 2.128
10-Day Moving Average 2.3
Average True Range 0.2372
ADX 17.74
+DI 25.6705
-DI 20.2676
Chandelier Exit (Long, 3 ATRs ) 2.0084
Chandelier Exit (Short, 3 ATRs ) 2.2716
Upper Bollinger Band 2.6132
Lower Bollinger Band 1.6428
Percent B (%b) 0.65
BandWidth 45.601504
MACD Line -0.0669
MACD Signal Line -0.1189
MACD Histogram 0.052
Fundamentals Value
Market Cap 319.23 Million
Num Shares 141 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -4.54
Price-to-Sales 98.61
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.66
Resistance 3 (R3) 2.70 2.60 2.60
Resistance 2 (R2) 2.60 2.50 2.59 2.57
Resistance 1 (R1) 2.44 2.44 2.39 2.40 2.55
Pivot Point 2.34 2.34 2.32 2.33 2.34
Support 1 (S1) 2.18 2.24 2.13 2.14 1.99
Support 2 (S2) 2.08 2.18 2.07 1.97
Support 3 (S3) 1.92 2.08 1.95
Support 4 (S4) 1.88